PWM
DMAC icon

Perigon Wealth Management’s DiaMedica Therapeutics DMAC Stock Holding History

Perigon Wealth Management’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$94.5K Buy
+13,957
New +$111K ﹤0.01% 1263
2025
Q3 		– Sell
-53,000
Closed -$207K – 1221
2025
Q2 		$207K Buy
+53,000
New +$207K ﹤0.01% 1000

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perigon Wealth Management's DMAC Position: Q1 2026 in Review

Perigon Wealth Management opened a new position in DiaMedica Therapeutics (DMAC) in Q1 2026: 13,957 shares worth $94.5K. The stake represents ﹤0.01% of the portfolio and ranks #1263 among its holdings. This is a return to the name: Perigon Wealth Management previously reported a position in DMAC as recently as Q2 2025.

Perigon Wealth Management first reported a position in DMAC in Q2 2025 and has held it in 2 quarters since. The position peaked at $207K in Q2 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Perigon Wealth Management held 13,957 shares of DiaMedica Therapeutics worth $94.5K as of Q1 2026.
  • DiaMedica Therapeutics was a new Perigon Wealth Management position in Q1 2026.
  • DiaMedica Therapeutics made up ﹤0.01% of Perigon Wealth Management's portfolio in Q1 2026, its #1263 holding.
  • Perigon Wealth Management first reported a position in DiaMedica Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • Perigon Wealth Management's DiaMedica Therapeutics position peaked at $207K in Q2 2025.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Perigon Wealth Management's 13F filing for Q1 2026, filed 10 Apr 2026.